RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (China)

Structure/Sequence

Molecular FormulaC15H9FN2O3

InChIKeyOOUGLTULBSNHNF-UHFFFAOYSA-N

CAS Registry775304-57-9

Clinical Trials associated with Ataluren

JPRN-jRCT2071220020

/ CompletedPhase 1IIT

A Single-Dose Study to Assess the Food Effect on the Pharmacokinetics and Tolerability of Ataluren (PTC124) in Healthy Japanese Subjects

Start Date24 Jun 2022

Sponsor / Collaborator-

NCT04336826

/ CompletedPhase 2

An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy

This study is designed to evaluate safety, tolerability, and pharmacokinetics (PK) in male children with nmDMD aged ≥6 months to <2 years treated daily for 24 weeks with orally administered ataluren 10, 10, and 20 milligrams/kilogram (mg/kg) (morning, mid-day, and evening dose, respectively).

Start Date29 Dec 2021

Sponsor / Collaborator

PTC Therapeutics, Inc.

CTR20211795

/ Active, not recruitingPhase 3

一项 ATALUREN (PTC124) 在无义突变型杜兴氏肌营养不良患者中的长期安全性、疗效和耐受性的开放性研究

[Translation] An open-label study of the long-term safety, efficacy, and tolerability of ATALUREN (PTC124) in patients with nonsense mutations in Duchenne muscular dystrophy

本研究的目标在于评估长期 Ataluren 10 mg/kg 、10 mg/kg 和 20 mg/kg 给药在完成 III 期研究 (PTC124-GD-041-DMD )后希望继续接受治疗的 nmDMD 受试者中的安全性、疗效和耐受性。将根据所有不良事件 (AE)、实验室检查异常、生命体征、心电图 (ECG)、超声心动图和体格检查结果的类型、频率、严重程度、时间以及与 Ataluren 的关系来描述 Ataluren 的安全性特征。Ataluren 的疗效将根据上肢功能 (PUL)、DMD 上肢患者报告结局指标 (PROM)、肺量测定、行走能力丧失 (LoA)和 6 分钟步行试验 (6MWT)较基线的变化来评估。

[Translation]

The objective of this study was to evaluate the safety, efficacy, and tolerability of long-term dosing of Ataluren 10 mg/kg, 10 mg/kg, and 20 mg/kg in nmDMD subjects who wished to continue treatment after completing a Phase III study (PTC124-GD-041-DMD). The safety profile of ataluren will be described based on the type, frequency, severity, timing, and relationship to ataluren of all adverse events (AEs), laboratory abnormalities, vital signs, electrocardiogram (ECG), echocardiogram, and physical examination findings. The efficacy of ataluren will be evaluated based on change from baseline in upper limb function (PUL), DMD upper limb patient-reported outcome measures (PROMs), spirometry, loss of ambulation ability (LoA), and 6-minute walk test (6MWT).

Start Date14 Sep 2021

Sponsor / Collaborator

ROVI Pharma Industrial Services SA

[+2]

100 Clinical Results associated with Ataluren

100 Translational Medicine associated with Ataluren

100 Patents (Medical) associated with Ataluren

288

Literatures (Medical) associated with Ataluren

01 Mar 2026·Molecular Therapy-Nucleic Acids

Beyond the stop: Oxadiazole TRIDs restore LRBA protein expression in nonsense-driven primary immunodeficiency

Article

Author: Lentini, Laura ; Moutschen, Michel ; Pibiri, Ivana ; Meier-Menches, Samuel M ; Pace, Andrea ; Zito, Antonino ; Ricci, Davide ; Vitale, Emanuele ; Borutzki, Yasmin ; Fiduccia, Ignazio ; Bileck, Andrea ; Colige, Alain ; Varrica, Riccardo ; Marino, Sefora

Nonsense mutations are among the genetic causes of LRBA (lipopolysaccharide-responsive beige-like anchor) deficiency, a rare autosomal-recessive immunodeficiency disorder. These mutations introduce premature stop codons, leading to the loss of LRBA protein expression. Following the recent market withdrawal of ataluren, the only approved translational readthrough-inducing drug (TRID), there is an urgent need for alternative therapeutic options. In this study, we investigated the efficacy of three 1,2,4-oxadiazole-based TRIDs-NV848, NV914, and NV930-using primary fibroblasts from a patient homozygous for the R1683X nonsense mutation. All compounds restored full-length LRBA protein with correct cytoplasmic localization, as confirmed by western blot and immunofluorescence, outperforming ataluren in readthrough efficiency. NV848 exhibited the strongest activity and uniquely increased LRBA mRNA levels, suggesting transcript stabilization. In contrast, NV930 and NV914 induced readthrough without stabilizing mRNA. Global proteomic profiling revealed minimal off-target effects for NV848, limited protein modulation by NV914, and widespread variations of 828 proteins by NV930, affecting pathways related to vesicular transport and mRNA splicing. However, network analysis revealed poor connectivity among differentially expressed proteins, with LRBA unrelated to any regulated cluster. These findings highlight the reported molecules as promising candidates for precision therapy in LRBA deficiency and shed light on the broader cellular impact of TRIDs.

01 Mar 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Unraveling the interaction mechanism between the genetic disease drug Ataluren and eukaryotic codon recognition factor 1/ human serum albumin through spectroscopic and nuclear magnetic resonance approaches

Article

Author: Tian, Hong ; Duan, Ran ; Yu, Juping ; Guo, Hanlin ; Peng, Zhengxiong ; Yu, Xinyu ; Liu, Wei

PTC124 (Ataluren) is a small molecule drug for the treatment of genetic diseases that has been shown to promote early termination codon read-through. In this study, the binding model of PTC124 to human serum albumin and eukaryotic stop codon recognition factor (eRF1) was established in vitro. In the cell model, the read-through effect of PTC124 on the stop codon was confirmed. Fluorescence analysis showed that PTC124 could spontaneously bind eRF1 and HSA, the binding constants were 3.132 ± 0.643 × 10⁴ and 2.963 ± 0.218 × 10⁵ L/mol (298 K), respectively. Thermodynamic analysis indicated that the binding to eRF1 was driven mainly by hydrophobic interactions, hydrogen bonding, and van der Waals forces, whereas the binding to HSA was driven primarily by hydrogen bonding and van der Waals forces. Structural analysis revealed perturbations in the secondary structure of both HSA and eRF1 induced by PTC124, while the overall native folds of the proteins were maintained. In addition, a binding model of the interaction between PTC124 and eRF1/HSA was established by molecular simulation and STD-NMR. The binding model described in this paper explains the interaction mechanism between PTC124 and its utility and transport targets at the molecular level, which is helpful for the design and synthesis of new molecules related to PTC124 structure and based on its mechanism of action.

01 Jan 2026·Genetics in medicine open

CFTR rescue in W1282X cystic fibrosis patient-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs)

Article

Author: Ramalho, Anabela S ; Pibiri, Ivana ; Lentini, Laura ; Vermeulen, Francois ; Perriera, Riccardo ; Pace, Andrea ; Vitale, Emanuele

Purpose:

Pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in dysfunctions of the CFTR protein, leading to cystic fibrosis (CF). This genetic disorder is characterized by severe symptoms in the respiratory and digestive systems.Currently, highly effective CFTR modulator treatments, such as the Elexacaftor-Tezacaftor-Ivacaftor combination, may represent the primary therapeutic option for approximately 82% of people with cystic fibrosis who have at least 1 F508del variant. However, the remaining 18% with rare CFTR variants, including nonsense variants, often lack access to these therapies. Nonsense variants lead to nonfunctional CFTR proteins and contribute to more severe CF symptoms. Research efforts focus on understanding the effects of these variants on disease severity and response to treatment.

Methods:

This study utilizes patient-derived intestinal organoids to evaluate the recovery of CFTR function in cells with nonsense variants.

Results:

Specifically, we tested 3 translational readthrough-inducing molecules: NV848, NV914, and NV930. Our studies highlighted the positive effect of NV848 on patient organoid swelling, improving CFTR channel function, whereas NV914 and NV930 did not induce organoid swelling, similar to PTC124 treatment.

Conclusion:

In conclusion, this study highlights the potential of translational readthrough-inducing molecules to restore CFTR function in cells with nonsense variants. By leveraging patient-derived intestinal organoids, our findings showed that NV848, in combination with Elexacaftor-Tezacaftor-Ivacaftor and the nonsense-mediated mRNA decay inhibitor NMDI14, enhances CFTR activity. This contributes to the development of personalized therapies for individuals with rare CFTR variants, addressing a critical unmet need in cystic fibrosis treatment.

News (Medical) associated with Ataluren

19 Feb 2026

·www.prnewswire.com

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025. "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs, and strong financial position, we look forward to continued success as we approach cash flow breakeven." Key Corporate Highlights Full-year 2025 product and royalty revenue of $831 million, exceeding guidance Global launch of Sephience off to strong start Q4 2025 revenue of $92 million, including $81 million revenue in the US and $11 million revenue ex-US Sephience total net revenue of $111 million in 2025 since launch 946 total patients on commercial therapy worldwide as of December 31, 2025 1,134 patient start forms received in the US as of December 31, 2025 Approval in Japan in December 2025; approval in Brazil in February 2026 Sephience global footprint expected to increase to 20 to 30 countries by end of 2026 In December 2025, PTC sold the remainder of its Evrysdi® (risdiplam) royalty to Royalty Pharma for $240 million upfront and up to $60 million in sales-based milestones; PTC maintains the right to receive a $150 million milestone from Roche based on single-year Evrysdi sales of $2.5 billion End-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington's disease (HD) program Alignment reached on design of global Phase 3 trial, INVEST-HD, which is planned to initiate in 1H 2026 FDA confirmed openness for potential Accelerated Approval pathway given significant unmet need Type C meeting with FDA held in December 2025 to discuss the vatiquinone Friedreich's ataxia program; FDA indicated that an additional study would be necessary to support NDA resubmission and meeting minutes stated that this could be an open-label study with a natural history control group Fourth Quarter and Full Year 2025 Financial Highlights Total revenues were $164.7 million for the fourth quarter of 2025, compared to $213.2 million for the fourth quarter of 2024. Total revenues were $1,730.7 million for full year 2025, compared to $806.8 million for full year 2024. Included in total revenues is collaboration and license revenue of $998.4 million for the full year 2025, related to the votoplam license and collaboration agreement with Novartis, which closed in January 2025. Total net product revenues were $184.0 million for the fourth quarter of 2025, compared to $150.1 million for the fourth quarter of 2024. Total net product revenues were $586.7 million for full year 2025, compared to $582.1 million for full year 2024. Translarna™ (ataluren) net product revenues were $39.0 million for the fourth quarter of 2025, compared to $89.1 million for the fourth quarter of 2024. Translarna net product revenues were $235.3 million for full year 2025, compared to $321.1 million for full year 2024. Emflaza® (deflazacort) net product revenues were $27.1 million for the fourth quarter of 2025, compared to $50.5 million for the fourth quarter of 2024. Emflaza net product revenues were $146.4 million for full year 2025, compared to $207.2 million for full year 2024. Roche reported Evrysdi full year 2025 sales of approximately 1,757 CHF million, resulting in royalty revenue of $244.2 million to PTC for full year 2025, compared to $203.9 million to PTC for full year 2024. Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $133.1 million for the fourth quarter of 2025, compared to $124.8 million for the fourth quarter of 2024. GAAP R&D expenses were $455.2 million for full year 2025, compared to $534.5 million for full year 2024. Non-GAAP R&D expenses were $124.3 million for the fourth quarter of 2025, excluding $8.8 million in non-cash, stock-based compensation expense, compared to $116.0 million for the fourth quarter of 2024, excluding $8.8 million in non-cash, stock-based compensation expense. Non-GAAP R&D expenses were $419.6 million for full year 2025, excluding $35.7 million in non-cash, stock-based compensation expense, compared to $497.9 million for full year 2024, excluding $36.6 million in non-cash, stock-based compensation expense. GAAP SG&A expenses were $96.9 million for the fourth quarter of 2025, compared to $84.7 million for the fourth quarter of 2024. GAAP SG&A expenses were $347.1 million for full year 2025, compared to $300.9 million for full year 2024. Non-GAAP SG&A expenses were $87.2 million for the fourth quarter of 2025, excluding $9.7 million in non-cash, stock-based compensation expense, compared to $76.3 million for the fourth quarter of 2024, excluding $8.4 million in non-cash, stock-based compensation expense. Non-GAAP SG&A expenses were $308.3 million for full year 2025, excluding $38.9 million in non-cash, stock-based compensation expense, compared to $262.9 million for full year 2024, excluding $38.0 million in non-cash, stock-based compensation expense. Net loss was $135.0 million for the fourth quarter of 2025, compared to net loss of $65.9 million for the fourth quarter of 2024. Net income was $682.6 million for full year 2025, compared to net loss of $363.3 million for full year 2024. Cash, cash equivalents, and marketable securities were $1,945.4 million on December 31, 2025, compared to $1,139.7 million on December 31, 2024. Shares issued and outstanding as of December 31, 2025, were 81,474,366. Full Year 2026 Financial Guidance Total product revenue of $700 to $800 million, representing a 19 to 36% increase from 2025, with the majority from Sephience GAAP R&D and SG&A expense of $775 to $815 million Non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million Non-GAAP Financial Measures In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below. Acronyms CHF: Confoederatio Helvetica Francs (Swiss francs) DMD: Duchenne muscular dystrophy FA: Friedreich's ataxia FDA: U.S. Food and Drug Administration GAAP: Generally Accepted Accounting Principles HD: Huntington's disease NDA: New Drug Application nmDMD: Nonsense mutation Duchenne muscular dystrophy PKU: Phenylketonuria R&D: Research and Development SG&A: Selling, General, and Administrative Today's Conference Call and Webcast Reminder To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at . A replay of the call will be available after completion of the call and will be archived on the company's website. About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit and follow on LinkedIn, X, Instagram and Facebook. For more Information Investors Ellen Cavaleri +1 (615) 618-6228 [email protected] Media Jeanine Clemente +1 (908) 912-9406 [email protected] Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "Full Year 2026 Financial Guidance", including with respect to (i) 2026 total product revenue guidance and (ii) 2026 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, meetings with regulatory agencies, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," "aim," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the U.S. on other regulatory bodies; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC's SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi or Waylivra. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law. SOURCE PTC Therapeutics, Inc. 21% more press release views with Request a Demo

Financial StatementPhase 3License out/inDrug ApprovalNDA

16 Feb 2026

·www.fiercepharma.com

PTC shuts down FDA approval bid for troubled Duchenne med Translarna

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation DMD after receiving feedback on its filing from the regulator. "FDA shared that based on its review to date, the data in the [New Drug Application] submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval of Translarna," Matthew Klein, M.D., PTC's chief executive, explained in a statement. PTC is "disappointed that FDA approval cannot be achieved," Klein said, citing the decades of development work that have gone into the company's protein restoration therapy. In a letter to the U.S. DMD community, PTC cited unresolvable "differences in data interpretation" with the FDA, Pharmaphorum reports. Translarna has a checkered past with the FDA and, despite scoring a thumbs-up in Europe back in 2014, recently met a major marketing setback there, as well. Stateside, the FDA initially declined to review PTC's Translarna application in 2016, telling the company its application was incomplete. About a year and a half later, the FDA formally rejected the drug, citing the need for PTC to run an additional trial "at a minimum" to better validate Translarna's effectiveness. The FDA also flagged other "nonclinical and [chemistry, manufacturing and controls] matters" in the approval bid. PTC announced it would make another attempt at U.S. approval in early 2024, pointing to "recent feedback" from the FDA. Now, that effort is ending without success. The drug has also suffered recent regulatory setbacks in the EU and, despite some pushback from European officials, the European Medicines Agency's human medicines committee ultimately decided not to renew the drug's conditional marketing authorization in late 2024. The European Commission, which has final say on approvals in the bloc, made the same call last March. European regulators blessed the med with a conditional nod in 2014 on results from a phase 2b study that favored Translarna over placebo on a six-minute walk test after 48 weeks of treatment. But that study and a subsequent trial did not produce statistically significant results on the metric. Back in the U.S., PTC also faced FDA friction around its Friedreich's ataxia candidate vatiquinone last year when the regulator denied approval of the candidate over a lack of "substantial evidence of efficacy" in the company's filing. Translarna, which goes by the generic moniker ataluren, is a protein restoration therapy that is designed to allow the formation of a functioning protein in patients with genetic disorders caused by nonsense mutations. PTC describes that type of mutation as an alteration in the genetic code that prematurely halts the synthesis of an essential protein. In the case of DMD, that protein would be dystrophin. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultDrug Approval

16 Feb 2026

·www.pharmaceutical-technology.com

PTC pulls Translarna NDA after unfavourable FDA feedback

It is currently unclear if PTC plans to re-file for Translarna’s US approval in DMD. Image credit: Michael Vi via ShutterStock.com. PTC Therapeutics has chosen to withdraw its resubmitted new drug application (NDA) for Duchenne muscular dystrophy (DMD) therapy, Translarna (ataluren), marking another significant setback in the drug’s US development programme. This call comes after the US Food and Drug Administration (FDA) voiced concerns over the drug’s efficacy in nonsense mutation DMD. According to PTC’s CEO, Matthew Klein, the regulator shared that based on its review thus far, the data used to support the application is “unlikely to meet the agency’s threshold of substantial evidence of effectiveness” to support Translarna’s approval. For this reason, the rare disease specialist has chosen to pull the NDA submitted to the FDA for Translarna in DMD, marking the third unsuccessful attempt by PTC to secure Translarna’s approval in the US. The company did not immediately respond to Pharmaceutical Technology’s request when asked if it plans to re-file for the drug’s approval with the FDA. The FDA previously refused to review the dystrophin protein restoration therapy in 2016, citing the incomplete nature of its associated NDA as the primary reason. On PTC’s second attempt to commercialise the drug in 2017, which followed a successful appeal of the FDA’s 2016 decision, the drug was once again rejected. This time, the decision was on the grounds that at least one additional study would be necessary to prove the drug’s efficacy in DMD. Translarna’s future in DMD market under question Alongside its troubles in getting the US regulatory greenlight, Translarna has also been subject to regulatory woes in the European market. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence While the drug first gained conditional marketing authorisation from the European Medicines Agency (EMA) in 2014, the agency later issued a negative opinion on renewing Translarna’s approval in 2024, following the review by the European Commission (EC) in late 2023. Now, the drug is only available to countries choosing to leverage Articles 117(3) and 5(1) of the EU Directive 2001/83, according to a 2025 statement from PTC. However, the drug remains approved for use in the UK. The drug is also available through the National Health Service (NHS). GlobalData, parent company of Pharmaceutical Technology , forecasts that Translarna will generate $73m in global sales during 2031 – down significantly from its $356m 2023 sales peak. Translarna is not the only DMD drug to receive a negative opinion from the FDA in recent months, as Capricor Therapeutics received a complete response letter (CRL) for its cell therapy, deramiocel, back in September 2025. In January 2026, the company issued an update, stating that it is currently compiling a clinical study report and supporting data in a bid to resubmit its application for deramiocel in DMD. Meanwhile, Sarepta’s approved DMD gene therapy, Elevidys (delandistrogene moxeparvovec), was also temporarily pulled from the US market following two non-ambulatory patient deaths after treatment. The FDA later reinstated Elevidys on the market following a review.

NDADrug ApprovalCell TherapyGene Therapy

100 Deals associated with Ataluren

External Link

KEGG	Wiki	ATC	Drug Bank
D09323	Ataluren	M09AX03	DB05016

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Muscular Dystrophy, Duchenne	European Union	PTC Therapeutics International Ltd.	31 Jul 2014
Muscular Dystrophy, Duchenne	Iceland	PTC Therapeutics International Ltd.	31 Jul 2014
Muscular Dystrophy, Duchenne	Liechtenstein	PTC Therapeutics International Ltd.	31 Jul 2014
Muscular Dystrophy, Duchenne	Norway	PTC Therapeutics International Ltd.	31 Jul 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystic Fibrosis	NDA/BLA	European Union	PTC Therapeutics, Inc.	-
Becker Muscular Dystrophy	Phase 3	Belgium	PTC Therapeutics, Inc.	26 Jan 2012
Duchenne and Becker Muscular Dystrophy	Phase 3	Belgium	PTC Therapeutics, Inc.	26 Jan 2012
Myositis	Phase 3	Belgium	PTC Therapeutics, Inc.	26 Jan 2012
Dyspnea	Phase 3	Belgium	PTC Therapeutics, Inc.	20 Feb 2009
Drug Resistant Epilepsy	Phase 2	United States	PTC Therapeutics, Inc.	01 Nov 2016
Epilepsies, Myoclonic	Phase 2	United States	PTC Therapeutics, Inc.	01 Nov 2016
Aniridia	Phase 2	United States	PTC Therapeutics, Inc.	31 Jan 2016
Aniridia	Phase 2	Canada	PTC Therapeutics, Inc.	31 Jan 2016
Mucopolysaccharidosis I	Phase 2	United Kingdom	PTC Therapeutics, Inc.	19 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03179631 \| NCT01826487 \| NCT00592553 (Study 041 \| Study 007 \| ACT DMD, AAN2024)	Phase 2/3	Muscular Dystrophy, Duchenne	-	Ataluren	afagqmyzme(ekfechdwfe) = cgjwcboepn ykacrskndq (qrwrfvsxlo ) View more	Positive	09 Apr 2024
NCT04336826 (CTgov)	Phase 2	Muscular Dystrophy, Duchenne	6	Ataluren	wzworsggkp = bqzriettyl bqpoqnjedx (zuyenozsbq, ctzrkvpgro - zbhnsedsqh) View more	-	01 Apr 2024
NCT03179631 (Study 041, AAN2023)	Phase 3	Muscular Dystrophy, Duchenne nonsense mutation (nm) DMD	-	Ataluren	kwugfzcfcd(udwlcituyo) = svgptcfatg sgcdzhdkun (kpsmeelfhc ) View more	Positive	25 Apr 2023
NCT03179631 (Study 041, MDA2023)	Phase 3	Muscular Dystrophy, Duchenne	-	Ataluren	mfhezfrehi(gmlpuvxmou) = qypxootfum qdbotoallb (rgswifykin ) View more	Positive	19 Mar 2023
NCT03179631 (Study 041, MDA2023)	Phase 3	Muscular Dystrophy, Duchenne	701	Ataluren	sphhnframg(ckpmfoclts) = lipxbgkvvz uwfttlduig (xsmwjzwsqj ) View more	Positive	19 Mar 2023
NCT00803205 \| NCT02139306 \| NCT02107859 (Pubmed \| Cochrane Database Syst Rev)	Not Applicable	Cystic Fibrosis	517	Ataluren and similar compounds	yxbomnisvt(szdjaajuiv) = Ataluren was associated with a higher rate of episodes of renal impairment (risk ratio 12.81, 95% confidence interval 2.46 to 66.65; P = 0.002; I2 = 0%; 2 trials, 517 participants) nvmlymajlv (jksabuxivc ) View more	-	03 Mar 2023
	Not Applicable	Cystic Fibrosis	517	Placebo		-	03 Mar 2023
NCT02647359 (STAR, CTgov)	Phase 2	Aniridia	39	Ataluren (Ataluren)	eumhsljktc(cbpohfcuen) = fmousgklrp ukmystafwp (dildcwdyyi, 7.425) View more	-	27 May 2022
NCT02647359 (STAR, CTgov)	Phase 2	Aniridia	39	Placebo+Ataluren (Placebo)	eumhsljktc(cbpohfcuen) = cjncuikdma ukmystafwp (dildcwdyyi, 11.809) View more	-	27 May 2022
NCT03648827 (CTgov)	Phase 2	Muscular Dystrophy, Duchenne	20	Ataluren	xpdqbxvtlt(etakcolmnx) = kogymbnvsl rnarekrehd (pvbdfiligh, rwerikeqzt - ybosaoydoj) View more	-	05 Apr 2022
NCT03796637 (CTgov)	Phase 2	Muscular Dystrophy, Duchenne	6	Ataluren	fjexqshtpg(buwlgxypsi) = ocikjdoozx xlzsvjlkni (mjxitkchsr, 0.05874) View more	-	05 Apr 2022
NCT01557400 (Study 019, MDA2021)	Phase 3	Muscular Dystrophy, Duchenne nonsense mutation	94	Ataluren 10, 10, 20 mg/kg	fcutjsapto(pbrvtbzsak) = a trend in delay in decline to predicted FVC <50% by ~1 year zkkmxhesfr (ligqpzifwr )	Positive	01 Mar 2021
NCT01557400 (Study 019, MDA2021)	Phase 3	Muscular Dystrophy, Duchenne nonsense mutation	94	Ataluren		Positive	01 Mar 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ataluren

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation